Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 1.00 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 1.00 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.64 |
| ▸ | SLC25A1 | P53007 | 1/20 | 0.64 |
| ▸ | EP300 | Q09472 | 1/20 | 0.57 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.57 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.57 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.55 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.55 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.55 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17927205 | 1.00 | DNMT1 (1.00) | DNMT1DNMT3AHKDC1SLC25A1EP300 | |
| SCHEMBL3620121 | 0.82 | DNMT1 (0.70) | DNMT1DNMT3ASLC25A1SLC10A2SLC10A1 | |
| SCHEMBL27920996 | 0.82 | DNMT1 (0.69) | DNMT1DNMT3ASLC25A1SLC10A2SLC10A1 | |
| SCHEMBL11636405 | 0.81 | DDX3X (0.73) | DNMT1DNMT3AHKDC1EP300KAT2B | |
| SCHEMBL31404890 | 0.81 | DNMT1 (0.67) | DNMT1DNMT3ASLC25A1SLC10A2SLC10A1 | |
| SCHEMBL11749307 | 0.79 | SLC25A1 (0.68) | DNMT1DNMT3ASLC25A1SLC10A2SLC10A1 | |
| SCHEMBL29918322 | 0.78 | SLC25A1 (1.00) | DNMT1DNMT3ASLC25A1SLC10A2SLC10A1 | |
| SCHEMBL30777865 | 0.78 | SLC25A1 (1.00) | DNMT1DNMT3ASLC25A1SLC10A2SLC10A1 | |
| SCHEMBL30000258 | 0.78 | SLC25A1 (1.00) | DNMT1DNMT3ASLC25A1SLC10A2SLC10A1 | |
| SCHEMBL5598171 | 0.78 | SLC25A1 (1.00) | DNMT1DNMT3ASLC25A1SLC10A2SLC10A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144056-A1 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) | 2025-05-08 | — | — | US | claimed |
| WO-2025063844-A1 | ENHANCEMENT OF T CELL MEDIATED THERAPIES WITH A DNA HYPOMETHYLATING AGENT AND A SUMOYLATION INHIBITOR | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2025-03-27 | — | — | WO | claimed |
| US-20240173358-A1 | Compositions and Methods for the Treatment of Conditions Associated with Nucleotide Repeat Expansion | THE GENERAL HOSPITAL CORPORATION | 2024-05-30 | — | — | US | claimed |
| EP-4308153-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NUCLEOTIDE REPEAT EXPANSION | The General Hospital Corporation (US) | 2024-01-24 | — | — | EP | claimed |
| US-20230374505-A1 | Human XIST Antisense Oligonucleotides for X Reactivation Therapy | THE GENERAL HOSPITAL CORPORATION | 2023-11-23 | — | — | US | claimed |
| WO-2023147573-A2 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGES (US) | 2023-08-03 | — | — | WO | claimed |
| EP-4192956-A2 | HUMAN XIST ANTISENSE OLIGONUCLEOTIDES FOR X REACTIVATION THERAPY | The General Hospital Corporation (US) | 2023-06-14 | — | — | EP | claimed |
| WO-2022197857-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NUCLEOTIDE REPEAT EXPANSION | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-22 | — | — | WO | claimed |
| US-20250144056-A1 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025063844-A1 | ENHANCEMENT OF T CELL MEDIATED THERAPIES WITH A DNA HYPOMETHYLATING AGENT AND A SUMOYLATION INHIBITOR | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2025-03-27 | — | — | WO | disclosed |
| US-20240327835-A1 | METHODS FOR REACTIVATING GENES ON THE INACTIVE X CHROMOSOME | THE GENERAL HOSPITAL CORPORATION | 2024-10-03 | — | — | US | disclosed |
| EP-4419209-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | Dana-Farber Cancer Institute, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240173358-A1 | Compositions and Methods for the Treatment of Conditions Associated with Nucleotide Repeat Expansion | THE GENERAL HOSPITAL CORPORATION | 2024-05-30 | — | — | US | disclosed |
| US-11912994-B2 | Methods for reactivating genes on the inactive X chromosome | THE GENERAL HOSPITAL CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023147573-A2 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGES (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4192956-A2 | HUMAN XIST ANTISENSE OLIGONUCLEOTIDES FOR X REACTIVATION THERAPY | The General Hospital Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023069943-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230053688-A1 | METHODS TO ALTER LATENCY IN EBV+ MALIGNANCIES | CORNELL UNIVERSITY | 2023-02-23 | — | — | US | disclosed |
| US-20230020545-A1 | METHODS FOR REACTIVATING GENES ON THE INACTIVE X CHROMOSOME | THE GENERAL HOSPITAL CORPORATION | 2023-01-19 | — | — | US | disclosed |
| WO-2022197857-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NUCLEOTIDE REPEAT EXPANSION | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-22 | — | — | WO | disclosed |